IMS data released today confirmed strong January Dacogen sales trend indicted by Oncln 2 weeks ago..sales rose by 25% in January. The absolute number, $9.54 MM translates to a $114 MM run rate. Assuming a modest 50 patient/month growth rate for the rest of the year, 2007 sales could be as high as $120 MM, or 20-30% higher than the guidance of $90-$100 MM give by partner MGI Pharma. We observe that while Dacogen is growing steadily, Vidaza was relatively flat at $11 MM in January.
I think its safe to say that dacogen will grow within the year due to little competition. Normally when a new product reaches market more doctors are willing to use it compared to old. However the real issue is supgen next product or the wanabee drug.